MIRA Pharmaceuticals (NASDAQ:MIRA) Trading 6.2% Higher – Should You Buy?

Shares of MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) traded up 6.2% on Wednesday . The stock traded as high as $1.22 and last traded at $1.20. 249,482 shares changed hands during mid-day trading, a decline of 25% from the average session volume of 332,859 shares. The stock had previously closed at $1.13.

MIRA Pharmaceuticals Trading Down 1.7 %

The company has a market capitalization of $19.05 million, a P/E ratio of -2.05 and a beta of 2.11. The company’s 50 day moving average is $1.19 and its 200-day moving average is $1.48.

MIRA Pharmaceuticals (NASDAQ:MIRA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.04. Analysts predict that MIRA Pharmaceuticals, Inc. will post -0.6 EPS for the current fiscal year.

Insider Buying and Selling at MIRA Pharmaceuticals

In related news, CEO Erez Aminov sold 55,410 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $1.39, for a total value of $77,019.90. Following the completion of the transaction, the chief executive officer now directly owns 1,105,790 shares in the company, valued at $1,537,048.10. The trade was a 4.77 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 6.65% of the stock is owned by company insiders.

Institutional Investors Weigh In On MIRA Pharmaceuticals

A hedge fund recently bought a new stake in MIRA Pharmaceuticals stock. International Assets Investment Management LLC acquired a new position in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 25,000 shares of the company’s stock, valued at approximately $29,000. International Assets Investment Management LLC owned about 0.15% of MIRA Pharmaceuticals at the end of the most recent quarter. Institutional investors and hedge funds own 35.16% of the company’s stock.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.